ArticleScientific reports2023
Synthesis of halloysite nanotubes decorated with green silver nanoparticles to investigate cytotoxicity, lipid peroxidation and induction of apoptosis in acute leukemia cells.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Study on Dielectric Properties of Nanoclay-Modified Disulfide-Containing Polyurea Composites.Nanomaterials (Basel, Switzerland) · 2026Article
- Unveiling the Distinct Effects of a Two-Dimensional Copper/Sodium Complex: Oxidative Stress on Erythrocytes and Cytotoxicity, Apoptosis, Drug Resistance, and Inflammation in Lung Cancer Cells.Anti-cancer agents in medicinal chemistry · 2026Article
- Phytocannabinoids and Nanotechnology in Lung Cancer: A Review of Therapeutic Strategies with a Focus on Halloysite Nanotubes.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Apoptotic efficacies of AgNPs formulated byOpen life sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia is the 15th most common cancer in adults and the first most common cancer in children under the age of five, and unfortunately, it accounts for many deaths every year. Since leukemia chemotherapy usually fails due to chemotherapy resistance and disease relapse, many efforts are being made to develop new methods of leukemia treatment. Therefore, for the first time, we decorated halloysite nanotubes (HNTs) with green silver nanoparticles (Ag NPs) with the help of Moringa Peregrina leaves extract to increase the solubility of Ag NPs and to use the protective ability of HNTs against lipid peroxidation in erythrocytes. Cell survival assay by the MTT method showed that HNTs-Ag NPs can decrease the survival of Jurkat T-cells to about 10% compared to the control. The IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.